<div id="parent_top_div"><div id="between_article_content_1-0"></div><p>A US-based subsidiary of drugmaker Cipla is recalling over 400 cartons of generic anti-cancer medication due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).</p>
<p>
	Warren (New Jersey)-based Cipla USA, Inc is recalling Nilotinib Capsules in two strengths (150 mg and 200 mg), the US health regulator said in its latest Enforcement Report.</p>
<p>
	The company is recalling the affected lot (271 and 164 cartons) due to &#34;failed tablet/capsule specifications&#34;, it stated.</p>
<p>
	Cipla USA, Inc initiated the Class III voluntary recall on February 18 this year.</p>
<p>
	According to the USFDA, a Class III recall is initiated in a &#34;situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences&#34;.</p><span style="height: 1px"> </span><div id="between_article_content_2-0"></div><div><div></div></div>
<p>
	Nilotinib works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.</p>
<p>
	India has the highest number of USFDA-compliant pharmaceutical plants outside of the US.</p>
<p>Indian pharmaceutical companies supply a substantial proportion of drugs to US residents, with four out of 10 of all prescriptions filled in the US in 2022 being supplied by Indian companies.</p></div>

坎伯兰药业

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

<p>Cipla USA, Inc. 是 Cipla 的子公司，因生产问题正在召回超过 400 箱 Nilotinib 胶囊（150 毫克和 200 毫克），这一消息由美国食品药品监督管理局（USFDA）报告。该自愿召回属于 III 类，始于 2 月 18 日，表明接触该产品不太可能导致不良健康后果。Nilotinib 用于阻止癌细胞的增殖。印度制药公司在向美国市场供应药物方面发挥着重要作用，2022 年它们填补了相当大比例的处方</p>

Cipla's US unit recalls 400+ cartons of generic anti-cancer drug: USFDA

Business Standard

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

Citius Pharma

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - Vanguard

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

Cipla 的美国分公司召回 400 多箱仿制抗癌药物：美国食品药品监督管理局（USFDA）